Alexion buys Pfizer preclinical gene therapy portfolio for $1B

28 Jul 2023
www.pharmamanufacturing.com
License out/inAcquisitionGene TherapyClinical Study
AstraZeneca's rare disease business Alexion has entered into a definitive purchase and license agreement with Pfizer for a portfolio of preclinical gene therapy programs and enabling technologies.
According to the agreement, Alexion will acquire and license Pfizer's early-stage rare disease gene therapy portfolio for a total amount of up to $1 billion. Alexion will also pay tiered royalties on sales as part of the arrangement.
The portfolio acquired includes preclinical gene therapy programs and innovative technologies, such as novel adeno-associated virus (AAV) capsids. AAV capsids have proven to be effective in delivering therapeutic gene cargo for gene therapy and gene editing.
By leveraging these resources with their existing capabilities and the recent acquisition of LogicBio, Alexion is hoping to develop and advance next-generation genomic medicines.
AstraZeneca's Alexion acquired LogicBio Therapeutics last year in a deal worth $68 million, aiming to advance rare disease treatments by utilizing LogicBio's technology platforms for gene therapy. LogicBio's research has focused on developing genetic medicine for pediatric patients with rare diseases, and they recently received FDA clearance to proceed with phase 1/2 trials for LB-001, a potential single-administration treatment for methylmalonic acidemia.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.